Triptans (Sumatriptan, Rizatriptan) for Post-Traumatic Headaches in PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | November 7, 2025 | 9 min read

Triptans are the first-line abortive treatment for post-traumatic migraines after head injury, whiplash, and TBI. Understanding how sumatriptan and rizatriptan appear in PI records — and how to distinguish them from CGRP preventives — helps attorneys build stronger headache-related demands.

Post-Traumatic Headache: A Ubiquitous PI Sequela

Post-traumatic headache (PTH) is one of the most frequently reported symptoms after traumatic brain injury, whiplash, and closed-head trauma. According to the International Classification of Headache Disorders (ICHD-3), PTH is a headache arising within seven days of a head injury or within seven days of regaining consciousness. In personal injury practice, it appears across virtually all accident categories: rear-end collisions, pedestrian knockdowns, motorcycle crashes, slip-and-falls, and sports injury cases.

When a PI client presents with post-traumatic headaches, their treating neurologist or primary care physician will typically pursue a two-track treatment approach:

1. Preventive medications — taken daily to reduce the frequency and severity of migraines (topiramate, amitriptyline, CGRP monoclonal antibodies like Aimovig, or oral CGRP antagonists like Qulipta)
2. Abortive medications — taken at the onset of an acute migraine attack to stop it before it progresses (triptans: sumatriptan, rizatriptan, zolmitriptan)

Triptans fill the abortive role. They are the most widely prescribed abortive migraine medications, and they appear frequently in PI pharmacy records.

[!KEY] Triptan prescriptions in a PI client's pharmacy record are objective evidence that the client is experiencing discrete, acute migraine episodes severe enough to require medication intervention. The refill frequency — typically 9 tablets per fill, filled monthly — quantifies how often attacks occur, which directly supports non-economic damages for pain and suffering.

How Triptans Work

Triptans are 5-HT1B/1D receptor agonists — they bind to serotonin receptors that cause vasoconstriction of intracranial blood vessels and inhibit the release of pro-inflammatory neuropeptides (especially CGRP) from trigeminal nerve endings.

This dual action — vascular constriction and neurogenic inflammation suppression — aborts the migraine attack within 1–2 hours of taking the medication for most patients.

According to FDA prescribing information, sumatriptan is indicated for the acute treatment of migraine with or without aura in adults.

Triptans available in the U.S. (by generic name / brand):

• Sumatriptan / Imitrex (oral, nasal spray, injection)
• Rizatriptan / Maxalt
• Zolmitriptan / Zomig
• Eletriptan / Relpax
• Naratriptan / Amerge
• Frovatriptan / Frova
• Almotriptan / Axert

Sumatriptan and rizatriptan are the most commonly prescribed in PI cases because of their generic availability and well-established clinical track records.

Triptans vs. CGRP Medications: What's the Difference?

A question PI attorneys encounter frequently: why is the client on both a triptan and a CGRP medication?

These two drug classes address different aspects of migraine treatment:

When a PI client is prescribed both a triptan and a CGRP preventive, it signals that:

1. Attack frequency is high enough to warrant prevention (typically ≥4 migraine days/month)
2. Attacks break through prevention and still require acute treatment
3. The migraine burden is substantial and medically managed at a clinical level

This combination is a strong economic damages signal — each medication class involves separate fills, separate costs, and separate documentation.

[!KEY] A PI client on both a daily CGRP preventive and a monthly triptan refill has documented the full migraine treatment picture: attacks are frequent enough to warrant prevention, and preventive therapy alone does not eliminate the need for abortive medication — a two-drug regimen that independently substantiates both the chronicity and the ongoing severity of post-traumatic migraine.

[!NOTE] Nurtec ODT (rimegepant) and Ubrelvy (ubrogepant) are oral CGRP antagonist gepants that serve as both abortive AND preventive agents. If you see Nurtec on the medication list, it may be doing double duty — abortive for acute attacks AND taken every other day for prevention. This single medication may appear more frequently in the refill record than triptans.

Triptan Records in the Demand Package

When sumatriptan or rizatriptan appears in a PI client's pharmacy record, it provides several useful data points:

Prescription date: Documents when the treating physician first identified migraine headaches as a clinical problem worth treating with a specific abortive agent.

Refill frequency: Standard triptan packs contain 9 tablets (sumatriptan) — the FDA-allowed monthly supply for controlled use. If the patient is refilling monthly, they are experiencing at least 1–2 migraines per month requiring medication. If they're refilling at the 10-day mark, the frequency is higher.

Multiple triptan prescriptions: A patient switching from sumatriptan to rizatriptan (or trying multiple triptans) indicates inadequate response to first-line treatment — a clinical escalation pattern that supports severity arguments.

Co-prescribed medications: Triptans are often co-prescribed with anti-nausea agents (ondansetron, promethazine) — a combination that documents migraines severe enough to cause vomiting.

[!TIP] In the demand letter narrative, describe not just that the client "has headaches" but that they are prescribed an abortive medication (sumatriptan) and a preventive (Qulipta or topiramate), refilling both monthly, indicating an ongoing high-frequency migraine condition that began after the accident and continues to require active medical management.

Defense Attacks on Triptan Prescribing — and Responses

"The client had migraines before the accident."

Response: Obtain a complete medication history pre- and post-accident. If triptans were not prescribed before the accident (or if the dosing frequency substantially increased after), the timing establishes causation. Post-traumatic headache is a recognized ICHD-3 diagnosis specifically tied to trauma onset.

"Headaches are subjective — there's no objective finding."

Response: The triptan prescription IS the objective finding. A physician who writes a prescription for an abortive migraine medication has made a clinical judgment that the patient is experiencing migraines worth treating with a specific pharmaceutical intervention. The pharmacy record documents that judgment.

"Headaches should have resolved within weeks."

Response: ICHD-3 distinguishes acute PTH (resolves within 3 months) from persistent PTH (continues beyond 3 months). Extended triptan prescribing — 6+ months of monthly fills — documents persistent PTH, a recognized chronic condition after head trauma.

[!KEY] Consistent monthly triptan refills for 6 or more months after the accident are the objective counterargument to the defense claim that post-traumatic headaches should have resolved quickly — the ICHD-3 persistent PTH classification, combined with a pharmacy record showing uninterrupted monthly fills, is clinically grounded and difficult for a defense expert to dismiss.

Pharmacy Lien Coverage for Triptans

Triptans prescribed by a treating physician for post-traumatic headaches are covered under pharmacy lien programs like LienScripts. At monthly refill frequency, the cumulative triptan cost across a 6–12 month treatment period is a meaningful line item in the economic damages calculation.

For patients who cannot access triptans through insurance — because their plan excludes PI-related claims, because they are uninsured, or because prior authorization is denied — a pharmacy lien program provides immediate access without out-of-pocket cost.

Related Resources

• CGRP Medications for Post-Traumatic Migraine
• Migraine After TBI or Whiplash: Medication Guide
• Topiramate for Post-Traumatic Headaches
• Qulipta (Atogepant) for Migraine in PI Cases
• Pharmacy Services for Personal Injury Clients

[!SOURCE] FDA Prescribing Information: Sumatriptan (Imitrex) — Approved indications, mechanism of action, dosing, and safety profile for sumatriptan tablets.

[!SOURCE] ICHD-3: Post-Traumatic Headache Classification — International Classification of Headache Disorders (3rd edition) diagnostic criteria for acute and persistent post-traumatic headache.